Background-Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with nonvalvular atrial fibrillation is unknown. Methods and Results-Cost-utility analysis using a patient-level Markov microsimulation decision analytic model with a lifetime horizon was undertaken to determine the lifetime costs, quality-adjusted life years, and incremental costeffectiveness ratio of LAA occlusion in relation to dabigatran and warfarin in patients with nonvalvular atrial fibrillation at risk for stroke without contraindications to oral anticoagulation. The analysis was performed from the perspective of the Ontario Ministry of Health and Long Term Care, the third-party payer for insured health services in Ontario, Canada. Effectiveness and utility data were obtained from the published literature. Cost data were obtained from the Ontario Drug Benefits Formulary and the Ontario Case Costing Initiative. Warfarin therapy had the lowest discounted quality-adjusted life years at 4.55, followed by dabigatran at 4.64 and LAA occlusion at 4.68. The average discounted lifetime cost was $21 429 for a patient taking warfarin, $25 760 for a patient taking dabigatran, and $27 003 for LAA occlusion. Compared with warfarin, the incremental cost-effectiveness ratio for LAA occlusion was $41 565. Dabigatran was extendedly dominated. Conclusions-Percutaneous LAA occlusion represents a novel therapy for stroke reduction that is cost-effective compared with warfarin for patients at risk who have nonvalvular atrial fibrillation. (A.M.) . The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
A trial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. 1 The prevalence of this disorder will increase with time, which poses a significant public health burden from AF-related stroke. Thus, the development of safe, effective, and economical strategies to reduce stroke risk in this population is critical. Warfarin traditionally has been used in patients with moderate to high risk for AF-related stroke because it reduces the risk of stroke compared with placebo. 2 Balanced against this is an increase in life-threatening bleeding, need for regular monitoring, and narrow therapeutic range, factors that have resulted in underprescribing of warfarin in clinical practice. 3 As a result, there has been tremendous study into alternatives to warfarin.
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The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial compared the novel oral anticoagulant (OAC) dabigatran to warfarin. 4 Dabigatran 150 mg twice daily was superior and 110 mg twice daily noninferior to warfarin in the prevention of ischemic strokes, with a lower rate of hemorrhagic stroke. This resulted in the approval of dabigatran for stroke prophylaxis in the setting of nonvalvular AF (NVAF) in Canada, 5 as well as a recommendation from the Canadian Cardiovascular Society that patients should receive this agent in preference to warfarin. 6 Strategies to exclude the left atrial appendage (LAA) from the systemic circulation have been developed with the hope of reducing the risk of stroke without the need for OAC. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) study compared percutaneous LAA occlusion to warfarin in patients with NVAF. 7 LAA occlusion was noninferior to warfarin with regard to the primary end point of stroke, cardiovascular death, and systemic embolism.
Novel OACs and percutaneous LAA occlusion are challenging the current paradigm for stroke prevention in patients with NVAF. Direct comparisons of these therapies are lacking. As such, the magnitude to which these new therapies reduce bleeding and stroke compared with warfarin, a determination of whether this offsets the increased costs, and the existence of any potential safety concerns remain unclear. Decision analytic modeling can address this gap in knowledge because it provides an explicit framework to incorporate all available evidence and thereby balance the potential benefits and tradeoffs of these strategies. In the present analysis, we assessed the projected quality-adjusted survival and costs associated with the strategies of stroke prevention with warfarin, dabigatran, or LAA occlusion in patients with NVAF. We believe that this will aid in both clinical decision making and health policy with regard to health technology adoption.
Methods

Study Design
We developed a Markov microsimulation model with 10 000 individual patient iterations to assess the costs and outcomes for patients with NVAF at risk of stroke. Three primary treatment strategies were evaluated: (1) Dose-adjusted warfarin with a target international normalized ratio of 2.0 to 3.0, (2) dabigatran, and (3) LAA occlusion.
Dabigatran dosing was based on that approved by Health Canada; all patients received 150 mg twice daily, except those ≥80 years of age or those ≥75 years old with a creatinine clearance between 30 and 50 mL/min, who were instead treated with dabigatran 110 mg twice daily. 5 The concomitant use of warfarin and dual-antiplatelet therapy with LAA occlusion was modeled on the PROTECT AF study. 7 Patients treated with LAA occlusion received warfarin for 6 weeks until assessment of a residual leak by transesophageal echocardiography. If no leak was identified, patients received dual-antiplatelet coverage from 6 weeks to 6 months, followed by aspirin indefinitely. If a leak was noted, patients continued taking warfarin for 6 months, at which point a repeat assessment for leak was performed. The presence of a persistent leak resulted in warfarin continuation indefinitely.
Outcomes of interest were life expectancy (measured in years), quality-adjusted life years (QALYs), costs (reported in 2012 Canadian dollars), and the incremental cost-effectiveness ratio. The model was analyzed from the perspective of the Ontario Ministry of Health and Long-Term Care, the third-party payer for government insured health services in the province of Ontario. Cycle length was 1 month, with a life-time time horizon. All health outcomes and costs were discounted at 5% per year according to recommendations from the Canadian Agency for Drug and Technology in Health. 8 Consistent with convention in economic analyses, we present our primary results by ordering the 3 strategies based on lowest to highest lifetime costs; we determined the incremental cost-effectiveness ratios based on the incremental cost and effectiveness compared with the next less inexpensive strategy. If a strategy was more expensive and less effective than its comparator, it was considered dominated and thus ruled out. In addition, we compared the strategies with the least expensive strategy and recalculated the incremental cost-effectiveness ratios. If a less expensive strategy had a higher incremental cost-effectiveness ratio than the alternative in the present analysis, it was less efficient per unit cost and considered to be extendedly dominated and thus not favorable.
Base Case
The baseline characteristics for simulated patients were obtained from a report on consecutive AF patients with nonvalvular AF presenting to an outpatient OAC clinic at an academic institution and are described in Table 1 . 9 The prevalence of stroke risk factors in the study population was similar to that reported in the RE-LY 4 and PROTECT AF 7 studies, as well as the general Canadian population. 10 The prevalence and incidence of patient comorbidities in the study population, including diabetes mellitus, hypertension, coronary artery and cerebrovascular disease, heart failure, liver disease, renal disease, alcohol consumption, and prior bleeding, were incorporated into the model given their impact on current and subsequent stroke and bleed risk (Table 1) . 1, 9, [11] [12] [13] 
Model Structure
A simplified model schematic is presented in Figure 1 . In any 1-month cycle, patients may remain in their current health state, die, or sustain a clinical event, including a stroke, bleed, or myocardial infarction (MI). Clinical events were consistent with those defined in the RE-LY trial. 4 The stroke and bleeding risk was updated with each cycle of the model to reflect new clinical events and changes in the prevalence of risk factors.
Transition Probabilities
Ischemic Stroke Risk and Severity
The risk of ischemic stroke for patients with NVAF not undergoing treatment was determined on the basis of the CHA 2 DS 2 VASc risk score (based on history of congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, and sex: Table I in the online-only Data Supplement), 21 which has been shown to yield a superior prediction of thromboembolic risk over the traditional CHADS 2 scoring system (based only on history of congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and history of stroke or transient ischemic attack), particularly when patients at low risk of stroke are assessed. Individuals with a score ≥2 require oral anticoagulation for stroke prevention. 6, 22 Once the baseline stroke risk was calculated, the odds ratio (OR) for stroke reduction was applied based on the treatment strategy ( Table 1 ). The OR for individuals undergoing warfarin therapy was 0.31. 17 The ORs in relation to warfarin for individuals taking dabigatran and undergoing LAA occlusion were obtained from the RE-LY 4 and PROTECT AF studies, 7 respectively.
We estimated that 8.2% of ischemic strokes were fatal, 40.2% were severe (nonfatal) strokes with substantial residual neurological deficits that prevented independent living, 42.5% were minor strokes with minimal residual neurological deficits (with no impact on independent living), and 9.1% were transient ischemic events with no residual neurological deficit (Table 1) . 18, 23, 24 Hemorrhagic strokes were considered a bleeding complication, as described below.
Bleeding Risk and Severity
The probabilities for bleeding were calculated with the HAS-BLED score (based on hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, and drugs/alcohol concomitantly; Table II in the online-only Data Supplement), which has consistently been shown to predict bleeding in patients with NVAF undergoing warfarin therapy, 9, 25, 26 has excellent performance for predicting intracranial hemorrhage, 26 and is endorsed by both the Canadian and European cardiovascular societies. 6, 22 The OR of major bleeding with dabigatran compared with warfarin was obtained from the RE-LY study, 4 and the OR of major bleeding within the first 6 months after LAA occlusion device implantation (OR=0.84) was obtained from the PROTECT AF study 7 ( Table 1 ). The long-term risk of major bleeding after successful LAA occlusion was assumed to be related to aspirin use (OR=0.62 compared with warfarin). 17 The incremental risk of bleeding associated with dual-antiplatelet therapy in patients who sustained an MI while taking an OAC was modeled with the use of data from the RE-LY study 19 (Table 1) . We assumed a 2-month course of dual-antiplatelet therapy in addition to OAC when an MI occurred. The proportion of bleeds classified as intracranial hemorrhage, major bleed, and minor bleed, as well as the risk of death with a bleeding event, was obtained from the published literature. 14, 15, 27 
Probability of Death
The baseline age-and sex-specific probability of death was obtained from Ontario life tables. These baseline probabilities were modified on the basis of the presence of clinical events. 14, 15, 28 We modeled a differential impact of clinical events based on the time from the incident event (Table 1) . For example, the OR for death after an intracranial hemorrhage was increased by 20.8 the first month after the event, 14 by 4.5 the following year, and by 2.2 between years 2 and 6. 15
Medication Discontinuation
Medication discontinuation rates were based on data from the RE-LY trial. We assumed that patients who discontinued OAC would do so within the first 2 years of initiation. 29 An intracranial hemorrhage Abnormal liver function includes chronic hepatic disease, cirrhosis, or biochemical evidence of significant hepatic derangement; abnormal renal function: chronic dialysis, renal transplantation, or serum creatinine ≥200 µmol/L; bleed history: anemia; excessive alcohol consumption: ≥8 drinks/wk; hypertension: systolic blood pressure >160 mm Hg; labile INR (international normalized ratio): time in therapeutic range <60%; major bleeding: any bleeding requiring hospitalization or causing a decrease in hemoglobin level >2 g/L or requiring blood transfusion that was not a hemorrhagic stroke; stroke: focal neurological deficit of sudden onset, diagnosed by a neurologist, lasting >24 hours; and vascular disease: peripheral artery disease, previous myocardial infarction, or aortic plaque. ICH indicates intracranial hemorrhage; INR, international normalized ratio; LAA, left atrial appendage; MI, myocardial infarction; OAC, oral anticoagulant; OR, odds ratio; and TIA, transient ischemic attack. would result in permanent discontinuation of OAC. 30 OAC was temporarily interrupted for 1 month after a major bleed and 2 days after a minor bleed. The model assumed that patients who discontinued OAC would use aspirin alone.
LAA Occlusion Complications
Procedure-related complications were modeled based on the PROTECT AF study 7 to include pericardial effusion that required drainage (4.8%), procedure-related stroke (1.1%), and device embolization (0.6%).
Quality-of-Life Estimates
Where high-quality studies were available, we used health state utilities derived from the general population with a consistent scaling (time trade-off; Table 2 ). 31, 32 The baseline utility for AF and the utility decrements associated with aspirin and warfarin were only available in studies of patients with AF 31, 37 ; however, when tested in 1-way sensitivity analyses as outlined below, this did not impact the robustness of our conclusions. The utility for dabigatran was assumed to be the same as for ximelagatran, an older OAC with a similar mechanism of action and dosing. 23 Because there are no published data on the utility decrement associated with LAA occlusion, we assumed this to be the same as that associated with a percutaneous coronary revascularization procedure. 38 Additional utility decrements were applied if a procedure-related complication (eg, stroke) occurred.
Costs
Costs, adjusted to 2012 Canadian dollars, reflected direct medical costs associated with medication or device use, hospitalization, and physician services ( Table 2 ). Unit costs for medications were obtained from the Ontario Drug Benefits Formulary. 33 The monthly cost for physician-monitored warfarin therapy was $36, 34 whereas it was $0.93 for aspirin, $31 for aspirin in addition to clopidogrel, and $99 for dabigatran (regardless of dose).
We estimated the cost associated with LAA occlusion procedures based on the cost of an LAA occlusion device ($8500), overnight hospitalization, cardiac catheterization laboratory costs, and physician fees ( Table 2) . Physician fees were obtained from the Ontario Schedule of Benefits 36 and included anesthesia administration, performance of a transesophageal echocardiogram at the time of implantation and during follow-up (6 weeks and 6 months if necessary), and device implantation. Given the absence of a specific physician fee for LAA occlusion procedures in Ontario, costs associated with the physician who implanted the device were estimated by combining the billing codes for performance of a transseptal puncture, angiogram, and percutaneous transluminal catheter-assisted closure of a secundum atrial septal defect, a procedure very similar to percutaneous LAA occlusion.
Costs associated with clinical events were obtained from the Ontario Case Costing Initiative, a province-wide initiative that reports cost data for acute inpatient events, complex continuing care, and rehabilitation 35 (Table 2) . International Classification of Diseases, Tenth Revision codes were used to identify typical case costs and average length of stay reported in the Ontario Case Costing Initiative for each health state ( Table 2 ).
Sensitivity Analysis
A probabilistic sensitivity analysis was performed with 1000 outer loops and 10 000 inner loops. β-Distributions were applied to all probabilities and utilities, γ-distributions to all costs, and lognormal distributions for all ORs and hazard ratios. Distributions were estimated with the means and SDs from source documentation. If a SD was not available, it was assumed to be one third of the mean. One-way deterministic sensitivity analyses were performed on key input parameters.
Model Verification
We verified our model by comparing the characteristics of the simulated patients to input parameters. Model outputs closely reflected input parameters (Tables 1 and 3 ). All analyses were performed with TreeAge Pro Suite 2012 Software Release 2 (TreeAge Software Inc, Williamstown, MA).
Results
Clinical Events
On the basis of the baseline distribution of CHA 2 DS 2 VASc scores, 8.8% of patients had a score of 2 and 25.7% had a score of 3. A total of 64.4% of patients had a moderate stroke risk, with a CHA 2 DS 2 VASc score ≥4, which corresponds to an annual stroke risk without therapy between 7.8% and 31.3% ( Table I in (Table 3) , whereas intracranial hemorrhage occurred in 0.9% of patients receiving warfarin, 0.6% receiving dabigatran, and 0.5% with LAA occlusion (Table 3 ). An overall reduction in bleeding was apparent with the strategy of LAA occlusion (Table 3 ).
Treatment Strategies and Discontinuation
Treatment discontinuation occurred with each strategy. Specifically, 16.3% of patients discontinued warfarin; for patients receiving dabigatran, only 15.8% received 150 mg twice a day, whereas 63.7% were taking 110 mg twice a day, and 20.5% discontinued this medication. Of patients treated with the LAA occlusion strategy, 9.3% had an unsuccessful device implantation and received long-term warfarin therapy. Of those with acute successful device implantation, 12.2% had a residual leak at 6 weeks that necessitated the use of warfarin for an additional 4.5 months, and 7.1% had a residual leak at 6 months and required warfarin indefinitely. Table 4 summarizes the nondiscounted and discounted results of the cost-effectiveness analysis. The average nondiscounted life expectancy in the warfarin group was 8.85 life years, whereas it was 8.94 and 9.01 years in the dabigatran and LAA occlusion groups, respectively. Warfarin therapy had the lowest discounted life expectancy of 6.71 years and a discounted quality-adjusted life expectancy of 4.55 QALYs. This was followed by dabigatran therapy, with 6.79 years and 4.64 QALYs. LAA occlusion had the greatest survival, with 6.81 years and 4.68 QALYs.
Life Expectancy, QALY, and Cost
The average discounted lifetime costs were $21 429 for warfarin, $25 760 for dabigatran, and $27 003 for LAA occlusion. Compared with warfarin, the incremental cost-effectiveness ratio was $46 560 for a strategy of dabigatran therapy and $41 565 for a strategy of LAA occlusion. As such, dabigatran therapy was extendedly dominated by LAA occlusion, given that dabigatran was more expensive per additional unit of effectiveness. Our model showed a considerable amount The utility decrement is a short-term 1-time decrement over 1 cycle. The utility decrement of a minor bleed is the same as a major bleed but for a length of 2 days. The utility decrement for a pericardial effusion and left atrial appendage occlusion device embolism was assumed to be similar to that for a major bleed and minor stroke, respectively. The cost for a left atrial appendage occlusion device embolism was assumed to be similar to that for coronary artery bypass graft surgery. The utility decrement and costs of a periprocedural stroke were assumed to be the same as for a minor stroke. Ongoing monthly costs for intracranial hemorrhage are continued for the patient's life. Ongoing monthly costs for a major stoke are continued for 2 years. Ongoing monthly costs for a minor stroke are continued for 1 month. Ongoing monthly costs for a myocardial infarction are continued for 2 years. ICH indicates intracranial hemorrhage; LAA, left atrial appendage; MI, myocardial infarction; TEE, transesophageal echocardiography; and TIA, transient ischemic attack. 
Sensitivity Analyses
The model was robust for the ranges of the majority of the variables on 1-way sensitivity analyses. However, the model was sensitive to 2 important parameters: the OR for bleeding with aspirin therapy and the OR for stroke with LAA occlusion. LAA occlusion was no longer cost-effective compared with dabigatran when the OR for bleeding with aspirin therapy compared with warfarin was >0.75 or if the OR for a stroke with LAA occlusion in relation to warfarin was >1.56.
Our probabilistic sensitivity analyses demonstrated that the strategy of LAA occlusion compared with warfarin was cost-effective in 43% of simulations using a willingnessto-pay threshold of $50 000 and in 47% of simulations using a willingness-to-pay threshold of $100 000 ( Figure 3 ).
Discussion
We evaluated the cost-effectiveness of 2 novel approaches for stroke prevention in NVAF and found that compared with warfarin, LAA occlusion and dabigatran are cost-effective. More importantly, our work suggests that a strategy of LAA occlusion is preferable to dabigatran therapy, based on current evidence.
Alternatives to warfarin are an area of very active research. The 2 nonwarfarin strategies evaluated in the present model represent potential paradigm shifts in the management of NVAF. Dabigatran is a new pharmacological agent, the main appeal of which is the lack of monitoring required, whereas LAA occlusion represents a radical nonpharmacological option. The present study is unique because it is the first comparison of these novel therapies for stroke prevention in NVAF. Although a direct head-to-head randomized comparison of these 2 approaches would be ideal, such a study would require a large number of patients with long follow-up to demonstrate noninferiority 39 and is unlikely to be forthcoming in the near future. Given the current market availability of these alternative novel OACs and LAA occlusion devices, we believe our work will stimulate clinicians and health policy makers to critically evaluate the merits of each approach.
From a methodological standpoint, our model presents a substantial advancement. The CHA 2 DS 2 VASc and HAS-BLED scores were used to predict stroke and bleeding, respectively, and were updated with each cycle, based on increasing age and the incidence of new risk factors. These enhancements result in more realistic simulated natural history.
In the present model, LAA occlusion was the preferred option over dabigatran. As seen in the 1-way sensitivity analyses, this conclusion was robust. Only 2 variables resulted in LAA occlusion not being the preferred option. Because prior studies have demonstrated the odds of bleeding with aspirin compared with warfarin are <0.75, 40,41 and a recent systematic review assessing various LAA occlusion devices strongly suggested that the annual risk of stoke with LAA occlusion devices is similar to that with warfarin, 42, 43 the true estimates of the odds of these 2 parameters are likely well less than the upper limit used in the present sensitivity analysis. Moreover, the cost-effectiveness of LAA occlusion is likely underestimated in the present model. Specifically, improvements 44 and 4.4% in the PREVAIL trial), which will favorably impact the cost-effectiveness of LAA occlusion. Additionally, the present results are extrapolated from clinical trials in which medication compliance is traditionally superior to real life, 45 which further underestimates the real-world cost-effectiveness of LAA occlusion with our model.
Limitations to our work merit discussion. First, estimates of the effectiveness of novel therapies were obtained from single randomized trials with restrictive enrollment and limited follow-up. It is possible that clinical event rates may change with time. Second, our base case represented a typical patient with NVAF eligible for OAC. Because the age of the base case was 76 years, it is possible that the present results may not be applicable to young patients. Third, the present results are based on Canadian costs and are reflective of medical practice in Ontario, Canada, where a single-payer, publically funded universal healthcare system exists. This may not be applicable to other jurisdictions with different models of healthcare delivery and funding. Fourth, because physician fees associated with LAA occlusion device implantation are not available currently in Ontario, conservative estimates were imputed into our model. Finally, given the limited data on the new strategies, we had to make multiple assumptions and obtain data from a limited number of sources. The variability between individual trials of the microsimulation and the parameter uncertainty apparent with the probabilistic sensitivity analyses reinforce the need for additional research to refine key input parameters. Our model can provide direction for researchers to target the areas within this field that would most benefit from further research through the value of partial perfect information analyses.
In conclusion, we found that novel stroke prevention strategies are cost-effective compared with warfarin therapy in patients at risk for stoke because of NVAF, with a strategy of LAA occlusion being most cost-effective. The present study reinforces the need for further study on the effectiveness, safety, and feasibility of adoption of this new technology. 
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